P
RARE icon

Pitcairn’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pitcairn’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,974
Closed -$217K – 700
2025
Q2 		$217K Sell
5,974
-726
-11% -$26.2K 0.01% 656
2025
Q1 		$243K Sell
6,700
-1,642
-20% -$68.3K 0.01% 644
2024
Q4 		$351K Sell
8,342
-2,242
-21% -$111K 0.02% 538
2024
Q3 		$588K Sell
10,584
-1,456
-12% -$74.2K 0.03% 385
2024
Q2 		$495K Buy
12,040
+4,083
+51% +$174K 0.03% 446
2024
Q1 		$372K Sell
7,957
-679
-8% -$32K 0.02% 516
2023
Q4 		$413K Buy
+8,636
New +$335K 0.03% 453

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Pitcairn's RARE Position: Q3 2025 in Review

Pitcairn sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 5,974 shares — an estimated $217K sold.

Pitcairn first reported a position in RARE in Q4 2023 and held it in 7 quarters. The position peaked at $588K in Q3 2024. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Pitcairn reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Pitcairn sold 5,974 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $217K.
  • Pitcairn first reported a position in Ultragenyx Pharmaceutical in Q4 2023 and held it in 7 quarters.
  • Pitcairn's Ultragenyx Pharmaceutical position peaked at $588K in Q3 2024.
  • 302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Pitcairn's 13F filing for Q3 2025, filed 12 Nov 2025.